Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies (Q40081496)

17 September 2017

Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies (English)

1 reference

17 September 2017

0 references

Laurent Coudeville

1

1 reference

17 September 2017

Nicolas Baurin

series ordinal

2

1 reference

17 September 2017

Elisabeta Vergu

series ordinal

3

1 reference

17 September 2017

language of work or name

English

0 references

publication date

21 November 2015

1 reference

17 September 2017

1 reference

17 September 2017

34

1 reference

17 September 2017

50

1 reference

17 September 2017

6417-6425

1 reference

The global distribution and burden of dengue

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Efficacy of a tetravalent dengue vaccine in children in Latin America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Assessing the potential of a candidate dengue vaccine with mathematical modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Challenges in the interpretation of dengue vaccine trial results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Direct and indirect effects in vaccine efficacy and effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Sequential Monte Carlo without likelihoods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Bayesian measures of model complexity and fit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Estimating dengue transmission intensity from sero-prevalence surveys in multiple countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Approaches to refining estimates of global burden and economics of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Revisiting Rayong: shifting seroprofiles of dengue in Thailand and their implications for transmission and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Research on dengue during World War II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Age-specificity of clinical dengue during primary and secondary infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Age and clinical dengue illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Potential opportunities and perils of imperfect dengue vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

"Herd immunity": a rough guide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Four key challenges in infectious disease modelling using data from multiple sources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Particle Markov chain Monte Carlo methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

A dynamic model of bovine tuberculosis spread and control in Great Britain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.11.023

10.1016/J.VACCINE.2015.11.023

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference